BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down - Here's Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $7.46, but opened at $7.23. BioCryst Pharmaceuticals shares last traded at $7.43, with a volume of 67,628 shares changing hands.

Analysts Set New Price Targets

A number of brokerages recently commented on BCRX. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a "buy" rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.60.

BioCryst Pharmaceuticals Trading Up 0.4 %

The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -12.28 and a beta of 1.79. The company has a 50 day moving average of $7.61 and a 200 day moving average of $7.41.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter last year, the firm earned ($0.19) EPS. The company's revenue for the quarter was up 35.1% on a year-over-year basis. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in BCRX. CWM LLC increased its holdings in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its holdings in shares of BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after buying an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after buying an additional 1,322 shares during the last quarter. nVerses Capital LLC bought a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $63,000. Finally, DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $74,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.